SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2025 | $30.00 | Buy | TD Cowen |
| 10/1/2025 | $8.00 | Outperform → In-line | Evercore ISI |
| 4/29/2025 | $20.00 | Overweight | Cantor Fitzgerald |
| 2/25/2025 | $15.00 | Outperform | Wedbush |
| 11/20/2023 | $10.00 | Overweight | JP Morgan |
| 9/18/2023 | $9.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/4/2023 | $11.00 | Hold → Buy | Jefferies |
| 7/13/2023 | $10.00 | Neutral → Buy | BofA Securities |
3 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00
Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00
Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– –BioCryst expects continued non-GAAP profitability in 2026 even after expected close of the proposed acquisition of Astria Therapeutics in Q1 2026– RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO (berotralstat) net revenue for the fourth quarter and full year 2025. The company also provided guidance for ORLADEYO net revenue, total revenue,
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the compa
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET. A link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases, driven by its deep commitment to improving the lives of people living with thes
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
EFFECT - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. "Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proceeds used to retire all remaining Pharmakon term debt— —Definitive agreement signed to acquire Astria Therapeutics; transaction expected to close Q1 2026— RESEARCH TRIANGLE
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)